首页> 外文会议> >Neovasculature in bone marrow stem cell mobilization for treating myocardial infarction
【24h】

Neovasculature in bone marrow stem cell mobilization for treating myocardial infarction

机译:骨髓干细胞动员中的新血管系统治疗心肌梗死

获取原文

摘要

Stem cell therapy offers a potential venue with which autologous bone marrow-derived stem cells (BMDSC) have the potential to regenerate functioning myocardial tissue in situ soon after myocardial infarction (MI). When they migrate to sites of MI, they can differentiate into cardiomyocytes, endothelial cells and nerve cells. We have developed a method to substantially increase the small amounts of circulating BMDSC following MI. Rebuilt myocardium must include a vascular network able to nourish it under diverse metabolic demands. We intend to quantify the viability and functionality of the microvasculature 1-4 weeks post MI with or without BMDSC mobilization to assess the ability of this neovasculature to deliver oxygen to the tissue. Fluorescent staining is used to visualize perfused and nonperfused neovasculature, and immunohistochemical staining is used for quantification of tissue hypoxia. Our preliminary results indicate that the decrease in the number of anatomical and perfused vessels after MI, is accompanied by a progressive increase in the distance to the nearest perfused blood vessel and the level of hypoxia in the infarcted tissue. These preclinical studies may aid in design of BMDSC mobilization strategies to treat humans with MI.
机译:干细胞疗法提供了一个潜在的场所,自体骨髓衍生干细胞(BMDSC)可以在心肌梗塞(MI)后立即在原位再生功能正常的心肌组织。当它们迁移到MI的部位时,它们可以分化为心肌细胞,内皮细胞和神经细胞。我们已经开发出一种可以显着增加心肌梗死后少量循环BMDSC的方法。重建的心肌必须包括能够在各种新陈代谢需求下滋养的血管网络。我们打算量化MI后1-4周后有无BMDSC动员的微脉管系统的生存能力和功能,以评估这种新脉管系统向组织输送氧气的能力。荧光染色用于可视化灌注和未灌注的新脉管系统,免疫组织化学染色用于定量组织缺氧。我们的初步结果表明,心肌梗死后解剖和灌注血管数量的减少伴随着到最近的灌注血管的距离的逐渐增加以及梗塞组织中的缺氧水平的增加。这些临床前研究可能有助于设计BMDSC动员策略,以治疗MI人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号